Accumulating evidence demonstrates that metabolic changes in the brain associated with
neuroinflammation, oxidative stress, and mitochondrial dysfunction play an important role in …

Alzheimer's disease (AD) is the most common cause of dementia worldwide and is
characterised pathologically by the accumulation of amyloid beta and tau protein …

Objective To propose a new hypothesis that GABAergic dysfunction in excitatory and
inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer's disease (AD). Background …

Alzheimer's disease (AD), an elderly neurodegenerative disorder with a high incidence and
progressive memory decline, is one of the most expensive, lethal, and burdening diseases …

The brain is one of the most energy-consuming organs in the body. Satisfying such energy
demand requires compartmentalized, cell-specific metabolic processes, known to be …

Alzheimer's disease (AD) is determined by various pathophysiological mechanisms starting
10–25 years before the onset of clinical symptoms. As multiple functionally interconnected …

The cerebrovascular-specific molecular mechanism in Alzheimer's disease (AD) was
investigated by employing comprehensive and accurate quantitative proteomics. Highly …

Alzheimer's disease (AD) is a major cause of dementia in older adults and is fast becoming
a major societal and economic burden due to an increase in life expectancy. Age seems to …

Alzheimer's disease (AD) is the most common cause of age-related neurodegeneration and
dementia, and there are no available treatments with proven disease-modifying actions. It is …

Background: Strong preclinical evidence suggests that exenatide, a glucagon-like peptide-1
(GLP-1) receptor agonist used for treating type 2 diabetes, is neuroprotective and disease …